Paula Green Sells 910 Shares of Twist Bioscience Co. (NASDAQ:TWST) Stock

Twist Bioscience Co. (NASDAQ:TWST) SVP Paula Green sold 910 shares of the firm’s stock in a transaction dated Friday, May 3rd. The stock was sold at an average price of $37.13, for a total transaction of $33,788.30. Following the completion of the sale, the senior vice president now directly owns 91,511 shares of the company’s stock, valued at $3,397,803.43. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

Paula Green also recently made the following trade(s):

• On Tuesday, April 2nd, Paula Green sold 229 shares of Twist Bioscience stock. The stock was sold at an average price of $32.74, for a total value of $7,497.46.
• On Wednesday, March 20th, Paula Green sold 200 shares of Twist Bioscience stock. The shares were sold at an average price of $33.52, for a total value of $6,704.00.
• On Wednesday, March 6th, Paula Green sold 600 shares of Twist Bioscience stock. The stock was sold at an average price of $37.43, for a total value of $22,458.00.

Twist Bioscience Price Performance

Shares of NASDAQ TWST opened at $41.40 on Thursday. Twist Bioscience Co. has a 1-year low of $11.81 and a 1-year high of $44.92. The business’s 50 day moving average is $34.18 and its two-hundred day moving average is $31.59. The stock has a market capitalization of $2.41 billion, a P/E ratio of -12.32 and a beta of 1.64.

Twist Bioscience (NASDAQ:TWST) last released its earnings results on Thursday, May 2nd. The company reported ($0.79) earnings per share for the quarter, beating the consensus estimate of ($0.84) by $0.05. The firm had revenue of $75.30 million for the quarter, compared to the consensus estimate of $70.70 million. Twist Bioscience had a negative return on equity of 31.61% and a negative net margin of 69.24%. The company’s revenue for the quarter was up 25.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($1.06) EPS. As a group, equities research analysts anticipate that Twist Bioscience Co. will post -3.17 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the business. Federated Hermes Inc. purchased a new position in Twist Bioscience in the 3rd quarter worth about $29,000. China Universal Asset Management Co. Ltd. raised its position in Twist Bioscience by 96.3% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 1,470 shares of the company’s stock valued at $30,000 after purchasing an additional 721 shares in the last quarter. EdgeRock Capital LLC purchased a new stake in shares of Twist Bioscience in the 4th quarter worth $30,000. Allspring Global Investments Holdings LLC grew its position in shares of Twist Bioscience by 51.8% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 3,453 shares of the company’s stock worth $70,000 after buying an additional 1,179 shares in the last quarter. Finally, Headlands Technologies LLC purchased a new position in shares of Twist Bioscience during the first quarter valued at $124,000.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on TWST shares. Barclays upped their price objective on Twist Bioscience from $40.00 to $45.00 and gave the stock an “overweight” rating in a research note on Friday, May 3rd. Robert W. Baird raised their target price on shares of Twist Bioscience from $39.00 to $40.00 and gave the stock an “outperform” rating in a research note on Friday, May 3rd. The Goldman Sachs Group upgraded shares of Twist Bioscience from a “neutral” rating to a “buy” rating and upped their price target for the stock from $25.00 to $45.00 in a research report on Wednesday, January 17th. Evercore ISI lifted their target price on shares of Twist Bioscience from $46.00 to $50.00 and gave the company an “outperform” rating in a research note on Friday, May 3rd. Finally, Scotiabank raised their price target on Twist Bioscience from $43.00 to $48.00 and gave the company a “sector outperform” rating in a report on Monday. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $42.50.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.